Prevalence and risk factors for HPV in HIV-positive young women receiving their first HPV vaccination.

TitlePrevalence and risk factors for HPV in HIV-positive young women receiving their first HPV vaccination.
Publication TypePublication
Year of Publication2012
AuthorsKahn JA, Burk RD, Squires KE, Kapogiannis BG, Rudy B, Xu J, Gonin R, Liu N, Worrell C, Wilson CM
JournalJ Acquir Immune Defic Syndr
Volume61
Issue3
Pagination390-9
Date Published2012 Nov 01
ISSN1944-7884
KeywordsAdolescent, Female, HIV Seropositivity, Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18, Humans, Logistic Models, Multivariate Analysis, Papillomavirus Infections, Papillomavirus Vaccines, Prevalence, Risk Factors, Sexual Behavior, Surveys and Questionnaires, Young Adult
Abstract

<p><b>BACKGROUND: </b>The objectives of this study were to describe the prevalence and risk factors for HPV infection among HIV-infected young women receiving their first quadrivalent HPV (HPV-6, -11, -16, and -18) vaccine dose.</p><p><b>METHODS: </b>We recruited 16- to 23-year-old women from 14 sites for an HPV vaccine trial. At the first visit, they completed a questionnaire and were tested for cervicovaginal HPV DNA (41 types) and HPV serology (4 vaccine types). Factors associated with any HPV, type-specific HPV, and high-risk (cancer-associated) HPV infections were identified using univariate and multivariable logistic regression.</p><p><b>RESULTS: </b>The mean age of participants (N = 99) was 21.4 years, 30.3% were on antiretroviral therapy, 74.7% were positive for ≥1 HPV DNA type, 53.5% for ≥1 high-risk type, 12.1% for HPV-16, and 5.1% for HPV-18. Most were HPV DNA negative and seronegative for HPV-16 (55.6%) and HPV-18 (73.7%); 45.5% were HPV DNA negative and seronegative for both HPV-16 and -18. Three variables were associated with high-risk HPV DNA in multivariable analysis: non-Hispanic black versus Hispanic ethnicity (adjusted odds ratio [AOR]: 7.06, 95% CI: 1.63 to 30.5), HIV viral load ≥ 400 versus <400 copies/mL (AOR: 3.47, 95% CI: 1.28 to 9.43), and frequency of vaginal sex in the past 90 days (AOR: 5.82, 95% CI: 1.30 to 26.11 for ≥6 vs 0 times).</p><p><b>CONCLUSIONS: </b>The prevalence of ≥1 HPV type was high in these young women, demonstrating the importance of vaccinating before sexual initiation. However, most women were HPV DNA negative and seronegative for high-risk vaccine-type HPV infection, supporting vaccination of sexually experienced HIV-positive young women.</p>

DOI10.1097/QAI.0b013e3182676fe3
Alternate JournalJ. Acquir. Immune Defic. Syndr.
PubMed ID22820809
PubMed Central IDPMC3480995
Grant ListP30CA013330 / CA / NCI NIH HHS / United States
U01 HD 040533 / HD / NICHD NIH HHS / United States
U01 HD040533 / HD / NICHD NIH HHS / United States
U01 HD 040474 / HD / NICHD NIH HHS / United States
U01 HD040474 / HD / NICHD NIH HHS / United States
P30 AI051519 / AI / NIAID NIH HHS / United States
AI-51519 / AI / NIAID NIH HHS / United States
NCRRUL1-RR-024134 / / PHS HHS / United States
M01RR020359 / RR / NCRR NIH HHS / United States
P30 CA013330 / CA / NCI NIH HHS / United States
UL1 RR024134 / RR / NCRR NIH HHS / United States
M01 RR020359 / RR / NCRR NIH HHS / United States